These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35694218)

  • 1. Dysregulation of Type 1 Interferon Signaling in Systemic Sclerosis: a Promising Therapeutic Target?
    Wu M; Assassi S
    Curr Treatm Opt Rheumatol; 2021 Dec; 7(4):349-360. PubMed ID: 35694218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis.
    Wu M; Skaug B; Bi X; Mills T; Salazar G; Zhou X; Reveille J; Agarwal SK; Blackburn MR; Mayes MD; Assassi S
    Ann Rheum Dis; 2019 Nov; 78(11):1583-1591. PubMed ID: 31439591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Janus kinase inhibitors for treatment of morphea and systemic sclerosis: A literature review.
    McGaugh S; Kallis P; De Benedetto A; Thomas RM
    Dermatol Ther; 2022 Jun; 35(6):e15437. PubMed ID: 35278019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of type 1 interferon in systemic sclerosis.
    Wu M; Assassi S
    Front Immunol; 2013 Sep; 4():266. PubMed ID: 24046769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of MicroRNA-618 Expression With Altered Frequency and Activation of Plasmacytoid Dendritic Cells in Patients With Systemic Sclerosis.
    Rossato M; Affandi AJ; Thordardottir S; Wichers CGK; Cossu M; Broen JCA; Moret FM; Bossini-Castillo L; Chouri E; van Bon L; Wolters F; Marut W; van der Kroef M; Silva-Cardoso S; Bekker CPJ; Dolstra H; van Laar JM; Martin J; van Roon JAG; Reedquist KA; Beretta L; Radstake TRDJ
    Arthritis Rheumatol; 2017 Sep; 69(9):1891-1902. PubMed ID: 28556560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luteolin sensitizes the antiproliferative effect of interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells.
    Tai Z; Lin Y; He Y; Huang J; Guo J; Yang L; Zhang G; Wang F
    Cell Signal; 2014 Mar; 26(3):619-28. PubMed ID: 24333668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kelch-like protein 42 is a profibrotic ubiquitin E3 ligase involved in systemic sclerosis.
    Lear TB; Lockwood KC; Larsen M; Tuncer F; Kennerdell JR; Morse C; Valenzi E; Tabib T; Jurczak MJ; Kass DJ; Evankovich JW; Finkel T; Lafyatis R; Liu Y; Chen BB
    J Biol Chem; 2020 Mar; 295(13):4171-4180. PubMed ID: 32071084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type I interferon dysregulation in Systemic Sclerosis.
    Skaug B; Assassi S
    Cytokine; 2020 Aug; 132():154635. PubMed ID: 30685202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis.
    Raschi E; Privitera D; Bodio C; Lonati PA; Borghi MO; Ingegnoli F; Meroni PL; Chighizola CB
    Arthritis Res Ther; 2020 Nov; 22(1):265. PubMed ID: 33168071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CXCL4 Antibody Reactivity Is Present in Systemic Sclerosis (SSc) and Correlates with the SSc Type I Interferon Signature.
    Lande R; Mennella A; Palazzo R; Pietraforte I; Stefanantoni K; Iannace N; Butera A; Boirivant M; Pica R; Conrad C; Chizzolini C; Riccieri V; Frasca L
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32707718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit.
    Kakkar V; Assassi S; Allanore Y; Kuwana M; Denton CP; Khanna D; Del Galdo F
    Curr Opin Rheumatol; 2022 Nov; 34(6):357-364. PubMed ID: 36125916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8.
    Ah Kioon MD; Tripodo C; Fernandez D; Kirou KA; Spiera RF; Crow MK; Gordon JK; Barrat FJ
    Sci Transl Med; 2018 Jan; 10(423):. PubMed ID: 29321259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis.
    Kondo M; Suzuki T; Kawano Y; Kojima S; Miyashiro M; Matsumoto A; Kania G; Błyszczuk P; Ross RL; Mulipa P; Del Galdo F; Zhang Y; Distler JHW
    Arthritis Res Ther; 2022 Sep; 24(1):210. PubMed ID: 36050717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implication of miR-126 and miR-139-5p in Plasmacytoid Dendritic Cell Dysregulation in Systemic Sclerosis.
    Chouri E; Wang M; Hillen MR; Angiolilli C; Silva-Cardoso SC; Wichers CGK; van der Kroef M; Bekker CPJ; Cossu M; van Bon L; Affandi AJ; Carvalheiro T; Pandit A; van Roon JAG; Beretta L; Burgering BMT; Radstake TRDJ; Rossato M
    J Clin Med; 2021 Jan; 10(3):. PubMed ID: 33573268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Long Non-coding RNA NRIR Drives IFN-Response in Monocytes: Implication for Systemic Sclerosis.
    Mariotti B; Servaas NH; Rossato M; Tamassia N; Cassatella MA; Cossu M; Beretta L; van der Kroef M; Radstake TRDJ; Bazzoni F
    Front Immunol; 2019; 10():100. PubMed ID: 30804934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TBK1: A key regulator and potential treatment target for interferon positive Sjögren's syndrome, systemic lupus erythematosus and systemic sclerosis.
    Bodewes ILA; Huijser E; van Helden-Meeuwsen CG; Tas L; Huizinga R; Dalm VASH; van Hagen PM; Groot N; Kamphuis S; van Daele PLA; Versnel MA
    J Autoimmun; 2018 Jul; 91():97-102. PubMed ID: 29673738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-throughput screening for small molecule inhibitors of the type-I interferon signaling pathway.
    Yuliantie E; Dai X; Yang D; Crack PJ; Wang MW
    Acta Pharm Sin B; 2018 Oct; 8(6):889-899. PubMed ID: 30505658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date.
    Felten R; Scher F; Sagez F; Chasset F; Arnaud L
    Drug Des Devel Ther; 2019; 13():1535-1543. PubMed ID: 31190735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic trioxide induces regulatory functions of plasmacytoid dendritic cells through interferon-
    Ye Y; Ricard L; Siblany L; Stocker N; De Vassoigne F; Brissot E; Lamarthée B; Mekinian A; Mohty M; Gaugler B; Malard F
    Acta Pharm Sin B; 2020 Jun; 10(6):1061-1072. PubMed ID: 32642412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.